Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.
about
Targeted Therapy in Biliary Tract CancersEverolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateCapecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.Therapeutic options for intrahepatic cholangiocarcinomaThe potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.Ceruloplasmin as a prognostic marker in patients with bile duct cancer.FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinomaProspective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.Immunotherapeutic Approaches to Biliary Cancer.Novel investigational therapies for treating biliary tract carcinoma.Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer.Safety profile and treatment response of everolimus in different solid tumors: an observational study.Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications.MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma.Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.
P2860
Q26798443-987363B8-C0A1-4F79-9674-34BD0C0098ABQ28067598-067A160B-D589-44A1-9DF6-9EC7240E49C8Q33428348-73AE821B-A64C-44B0-87D3-6E0701042B70Q33621529-856D6697-BFF5-485C-A764-67D9705BA414Q33656860-DCCE6D92-CEB9-4B90-986D-D558119EAFF1Q33709983-2FADB6CC-A57D-4F7C-ABEB-D04432EDF106Q35078039-DFC22C31-690A-4D94-ADCF-C5E904EDCC8EQ36318871-74AFA7B8-19C8-4981-ADD7-A6F61A747B06Q37017110-18E15147-FED5-4483-A341-86DF945D8A8BQ38577917-A58DEFAB-85ED-4BAC-A764-F127501AD163Q38678966-546C698F-15B1-4C13-A694-C08113E30052Q38703148-7C37909B-4135-4F82-BB11-F5FF11A532E3Q38799963-30318E16-F852-4997-A97F-F83492261190Q38903263-73384219-39FB-45CE-ABC8-52C229A919ECQ39141798-437DEFEC-0E67-40AF-8F5A-4F0EF5894183Q39289707-2A1C7F3E-4500-4974-A635-F4904D5C5085Q47429093-F722DE83-0AB6-4DBD-BDD4-EB577352A406Q52661828-46D828C9-BEBC-4BDD-8B5A-699EDDE223B3
P2860
Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Activity and safety of RAD001 ...... herapy: a phase II ITMO study.
@ast
Activity and safety of RAD001 ...... herapy: a phase II ITMO study.
@en
type
label
Activity and safety of RAD001 ...... herapy: a phase II ITMO study.
@ast
Activity and safety of RAD001 ...... herapy: a phase II ITMO study.
@en
prefLabel
Activity and safety of RAD001 ...... herapy: a phase II ITMO study.
@ast
Activity and safety of RAD001 ...... herapy: a phase II ITMO study.
@en
P2093
P2860
P50
P356
P1433
P1476
Activity and safety of RAD001 ...... herapy: a phase II ITMO study.
@en
P2093
A Bertolini
A Mambrini
C Iannacone
M Platania
P2860
P304
P356
10.1093/ANNONC/MDU175
P577
2014-05-14T00:00:00Z